From DARPA (US Military) below. Big Ouch for @Joes Place & @*33*
SARS-CoV-2 is an American-created recombinant bat vaccine, or its precursor virus. It was created by an EcoHealth Alliance program at the Wuhan Institute of Virology (WIV), as suggested by the reporting surrounding the lab leak hypothesis. The details of this program have been concealed since the pandemic began. These details can be found in the EcoHealth Alliance proposal response to the DARPA PREEMPT program Broad Agency Announcement (BAA) HR00118S0017, dated March 2018 – a document not yet publicly disclosed.
The contents of the proposed program are extremely detailed. Peter Daszak lays out step-by-step what the organization intends to do by phase and by location. The primary scientists involved, their roles, and their institutions are indicated. The funding plan for the WIV work is its own document. The reasons why nonpharmaceutical interventions like masks and medical countermeasures like the mRNA vaccines do not work well can be extrapolated from the details. The reasons why the early treatment protocols work as curatives are apparent.
SARS-CoV-2’s form as it emerged is likely as a precursor, deliberately virulent, humanized recombinant SARSr-CoV that was to be reverse engineered into a live attenuated SARSr-CoV bat vaccine. Its nature can be determined from analysis of its genome with the context provided by the EcoHealth Alliance proposal. Joining this analysis with US intelligence collections on Wuhan will aid this determination.
DARPA rejected the proposal because the work was too close to violating the gain-of-function (GoF) moratorium, despite what Peter Daszak says in the proposal (that the work would not). As is known, Dr. Fauci with NIAID did not reject the proposal. The work took place at the WIV and at several sites in the US, identified in detail in the proposal.
DRASTIC independently assesses that the tone of the proposal (see for instance the ‘our cave complex’) and the deep suggested involvement of some of the WIV parties (Shi Zheng Li employed half-time for 3 years – paid via the grant – and invited to DARPA headquarters at Arlington), may not have helped either – especially in the absence of any DURC risk mitigation program.
SARS-CoV-2, hereafter referred to as SARSR-CoV-WIV, is a synthetic spike protein chimera engineered to attach to human ACE2 receptors and inserted into a recombinant bat SARSr-COV backbone. It is likely a live vaccine not yet engineered to a more attenuated state that the program sought to create with its final version. It leaked and spread rapidly because it was aerosolized so it could efficiently infect bats in caves, but it was not ready to infect bats yet, which is why it does not appear to infect bats. The reason the disease is so confusing is because it is less a virus than it is engineered spike proteins hitch-hiking a ride on a SARSr-CoV quasispecies swarm. The closer it is to the final live attenuated vaccine form, the more likely that it has been deattenuating since initial escape in August 2019.
The gene-encoded, or “mRNA,” vaccines work poorly because they are synthetic replications of the already-synthetic SARSr-CoV-WIV synthetic spike proteins and possess no other epitopes. The mRNA instructs the cells to produce synthetic copies of the SARSr-CoV-WIV synthetic spike protein directly into the bloodstream, wherein they spread and produce the same ACE2 immune storm that the recombinant vaccine does. Many doctors in the country have identified that the symptoms of vaccine reactions mirror the symptoms of the disease, which corroborates with the similar synthetic nature and function of the respective spike proteins.
The vaccine recipient has no defense against the bloodstream entry, but their nose protects them from the recombinant spike protein quasispecies during “natural infection” (better termed as aerosolized inoculation).
Ivermectin (identified as curative in April 2020) works throughout all phases of illness because it both inhibits viral replication and modulates the immune response. Of note, chloroquine phosphate (Hydroxychloroquine, identified April 2020 as curative) is identified in the proposal as a SARSr-CoV inhibitor, as is interferon (identified May 2020 as curative).
SARS-CoV-2 is an American-created recombinant bat vaccine, or its precursor virus. It was created by an EcoHealth Alliance program at the Wuhan Institute of Virology (WIV), as suggested by the reporting surrounding the lab leak hypothesis. The details of this program have been concealed since the pandemic began. These details can be found in the EcoHealth Alliance proposal response to the DARPA PREEMPT program Broad Agency Announcement (BAA) HR00118S0017, dated March 2018 – a document not yet publicly disclosed.
The contents of the proposed program are extremely detailed. Peter Daszak lays out step-by-step what the organization intends to do by phase and by location. The primary scientists involved, their roles, and their institutions are indicated. The funding plan for the WIV work is its own document. The reasons why nonpharmaceutical interventions like masks and medical countermeasures like the mRNA vaccines do not work well can be extrapolated from the details. The reasons why the early treatment protocols work as curatives are apparent.
SARS-CoV-2’s form as it emerged is likely as a precursor, deliberately virulent, humanized recombinant SARSr-CoV that was to be reverse engineered into a live attenuated SARSr-CoV bat vaccine. Its nature can be determined from analysis of its genome with the context provided by the EcoHealth Alliance proposal. Joining this analysis with US intelligence collections on Wuhan will aid this determination.
DARPA rejected the proposal because the work was too close to violating the gain-of-function (GoF) moratorium, despite what Peter Daszak says in the proposal (that the work would not). As is known, Dr. Fauci with NIAID did not reject the proposal. The work took place at the WIV and at several sites in the US, identified in detail in the proposal.
DRASTIC independently assesses that the tone of the proposal (see for instance the ‘our cave complex’) and the deep suggested involvement of some of the WIV parties (Shi Zheng Li employed half-time for 3 years – paid via the grant – and invited to DARPA headquarters at Arlington), may not have helped either – especially in the absence of any DURC risk mitigation program.
SARS-CoV-2, hereafter referred to as SARSR-CoV-WIV, is a synthetic spike protein chimera engineered to attach to human ACE2 receptors and inserted into a recombinant bat SARSr-COV backbone. It is likely a live vaccine not yet engineered to a more attenuated state that the program sought to create with its final version. It leaked and spread rapidly because it was aerosolized so it could efficiently infect bats in caves, but it was not ready to infect bats yet, which is why it does not appear to infect bats. The reason the disease is so confusing is because it is less a virus than it is engineered spike proteins hitch-hiking a ride on a SARSr-CoV quasispecies swarm. The closer it is to the final live attenuated vaccine form, the more likely that it has been deattenuating since initial escape in August 2019.
The gene-encoded, or “mRNA,” vaccines work poorly because they are synthetic replications of the already-synthetic SARSr-CoV-WIV synthetic spike proteins and possess no other epitopes. The mRNA instructs the cells to produce synthetic copies of the SARSr-CoV-WIV synthetic spike protein directly into the bloodstream, wherein they spread and produce the same ACE2 immune storm that the recombinant vaccine does. Many doctors in the country have identified that the symptoms of vaccine reactions mirror the symptoms of the disease, which corroborates with the similar synthetic nature and function of the respective spike proteins.
The vaccine recipient has no defense against the bloodstream entry, but their nose protects them from the recombinant spike protein quasispecies during “natural infection” (better termed as aerosolized inoculation).
Ivermectin (identified as curative in April 2020) works throughout all phases of illness because it both inhibits viral replication and modulates the immune response. Of note, chloroquine phosphate (Hydroxychloroquine, identified April 2020 as curative) is identified in the proposal as a SARSr-CoV inhibitor, as is interferon (identified May 2020 as curative).